Amicus Therapeutics Inc

Amicus Therapeutics — Investor Presentation (September 2023)

32 slides from Amicus Therapeutics's investor presentation, Sep 27, 2023

  1. Slide 1: Corporate Overview September 2023

    AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: A Rare Company

    3 A Rare Company Patient-dedicated, rare disease biotechnology company with sustained double-digit revenue growth, a global commercial infrastructure, and late-stage development capabilities GLOBAL COMMERCIAL ORGANIZATION EMPLOYEES in 20 Countries GALAFOLD & POMBILITI + OPFOLDA Gene Therapy Platform

  4. Slide 4: 2023 Strategic Priorities

    2023 Strategic Priorities Sustain double-digit Galafold revenue growth of 14-18% at CER1 Secure FDA, EMA, and MHRA approvals for AT-GAA Initiate successful global launches of AT-GAA Advance best-in-class, next-generation Fabry and Pompe pipeline programs and capabilities Maintain strong financial po

  5. Slide 5: Amicus Pipeline

    5 Amicus Pipeline Streamlined rare disease pipeline with focus on Fabry disease and Pompe disease franchises INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold® (migalastat) Fabry Gene Therapy Next-Generation Chaperone POMPE FRANCHISE PombilitiTM + Opfo

  6. Slide 6: Galafold (migalastat) Continued Growth

    6 Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease

  7. Slide 7: Global Fabry Market

    7 Global Fabry Market Believed to be significantly underdiagnosed – Newborn screening studies suggest Fabry is one of the more prevalent genetic diseases (~1:1,000 to ~1:4,000 incidence) In 2021 and 2022, Galafold was the fastest growing Fabry treatment and the greatest contributor to market growth

  8. Slide 8: 2023 Galafold Success

    8 2023 Galafold Success (as of June 30, 2023) Building on Galafold’s success and leveraging leadership position to drive continued growth Galafold is indicated for adults with a confirmed diagnosis of Fabry disease and an amenable variant. The most common adverse reactions reported with Galafold (≥1

  9. Slide 9: Galafold Performance

    9 Galafold Performance Raising FY23 revenue growth guidance to 14% to 18% at CER Global mix of switch (~45%) and previously untreated patients (~55%)3 Compliance and adherence over 90%+ Expect non-linear quarterly growth to continue due to uneven ordering patterns and FX fluctuations FY16 FY17 FY18

  10. Slide 10: Galafold Global Commercial Momentum

    10 Galafold Global Commercial Momentum (as of June 30, 2023) Strong patient demand and performance against key metrics lay the foundation for continued double-digit growth in 2023 10 Continued penetration into existing markets Further uptake in diagnosed untreated population Continued geographic exp

  11. Slide 11: Pombiliti + Opfolda: Potential New Standard of Care

    11 Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Potential to establish a new standard of care for people living with Pompe disease

  12. Slide 12: Late-Onset Pompe Disease (LOPD) Overview

    12 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Diagnosed at different stages of life, from childhood to adulthood Symptoms include progressive muscle weakness, particularly skeletal and respiratory muscles, that worsens over time Respiratory failure is a maj

  13. Slide 13: Global Pompe Market

    13 Global Pompe Market Global Pompe disease market growth continues to be driven by the diagnosis of new patients An estimated 3,500-4,000 Pompe patients globally are being treated by ERT3 Global Pompe Market of ~$1.2B in 2022 and Tracking toward $1.8B+ by 20271 (millions) $0 $200 $400 $600 $800 $1,

  14. Slide 14: AT-GAA: An Innovative Approach to Pompe Disease

    14 AT-GAA: An Innovative Approach to Pompe Disease Our scientists created a uniquely glycosylated and highly phosphorylated ERT (cipaglucosidase alfa) that significantly enhances targeting to key affected muscles AT-GAA is a two-component therapy combining cipaglucosidase alfa, an ERT, with miglusta

  15. Slide 15: WORLDSymposium Update – Phase OLE of AT-GAA in LOPD

    15 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Number of patients (n) Mean (SD) baseline 6MWD (% predicted): Cipa/mig–cipa/mig = 56.1 (16.03) Alg/pla–cipa/mig = 54.8 (17.68) Mean (SD) week 104 6MWD (% predicted): Cipa/mig–cipa/mig = 60.8 (18.07) Alg/pla–cipa/mig = 54.3 (21.86) 6 Cipa/mig–c

  16. Slide 16: SSIEM Update – PROPEL Effect Size Analysis

    16 SSIEM Update – PROPEL Effect Size Analysis in ERT-Experienced Adults Post hoc analysis shows majority of study parameters demonstrated stabilization or improvement after switching from SoC to Pombiliti + Opfolda Significant improvement was only observed for (unadjusted mean CFBL) QoL: PROMIS–Dysp

  17. Slide 17: Global Regulatory Status

    17 17 1Data on file Global Regulatory Status Expect regulatory approvals and launch into the three largest Pompe markets in 2023 Pombiliti® + Opfolda® now approved in the U.K. Pombiliti® + Opfolda® now approved in the EU Based on recent engagements with the U.S. FDA, approval expected in the coming

  18. Slide 18: Ongoing Clinical Studies and Expanded Access Mechanisms

    18 Ongoing Clinical Studies and Expanded Access Mechanisms Ongoing clinical studies in children and adolescents1 with LOPD and infantile-onset Pompe disease (IOPD) Multiple expanded access mechanisms in place, including in the U.S., U.K., Germany, France, Japan, and others At time of first regulator

  19. Slide 19: Pombiliti + Opfolda EU Opportunity

    19 Pombiliti + Opfolda EU Opportunity Strong indication statement: – Pombiliti® (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser Opfolda® (miglustat) for the treatment of adults with late-onset Pompe disease (acid α glucosidase [GAA] def

  20. Slide 20: Launch of Pombiliti + Opfolda Underway in the EU

    20 Launch of Pombiliti + Opfolda Underway in the EU Experienced and passionate rare disease commercial and medical organization supporting early days of launch Access and Reimbursement Positive Interactions with Payors Focus on broad patient access Country-by-country reimbursement process Active dis

  21. Slide 21: Corporate Outlook

    21 Corporate Outlook Delivering on our mission for patients and shareholders

  22. Slide 22: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability 22 Sustain Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $180.8M 1H 2023 revenue, +16% YoY operational growth 2023 Galafold revenue growth guidanc

  23. Slide 23: Positioned for Significant Value Growth

    23 Positioned for Significant Value Growth Focused on execution and driving sustainable double-digit revenue growth on path to profitability Continue to bring Galafold® to as many patients as possible, sustain double-digit operational revenue growth Successful launch of AT-GAA for people living with

  24. Slide 24: True Measure of Success: Impacting the Lives of People Living with Rare Diseases

    24 True Measure of Success: Impacting the Lives of People Living with Rare Diseases YE17 2023+ >2,000 Patients* Thousands of Patients* YE22 >350 Patients* *Clinical & commercial, all figures approximate

  25. Slide 25: Appendix

    Therapeutics Appendix

  26. Slide 26: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Total operating expenses - as reported GAAP $104,249 $133,147 $221,213 $279,619 Research and development: Stock-based compensation

  27. Slide 27: 2023 Environmental, Social, & Governance (ESG) Snapshot

    27 2023 Environmental, Social, & Governance (ESG) Snapshot Board of Directors Committed to ongoing Board refreshment and diversity of background, gender, skills, and experience: 80% Board Independence 60% Overall Board Diversity Address a rare genetic disease First-in-class or best-in-class Impart m

  28. Slide 28: WORLDSymposium Update – 6MWD in OLE

    28 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Improvement from the PROPEL baseline in % predicted 6MWD for the cipa/mig group was maintained throughout the OLE for ERT-experienced and ERT-naïve patients ERT-experienced and -naïve patients treated with cipa/mig throughout showed durable im

  29. Slide 29: WORLDSymposium Update – Sitting % Predicted FVC

    29 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Sitting % predicted FVC remained stable in ERT-experienced and ERT-naïve patients throughout the OLE for both PROPEL treatment groups ERT-experienced patients treated with cipa/mig throughout remained stable, while patients who received alg/pl

  30. Slide 30: WORLDSymposium Update – Serum CK

    30 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Cipa/mig treatment was associated with a durable reduction in serum CK during PROPEL and the OLE in both ERT-experienced and ERT-naïve patients ERT-experienced and -naïve patients treated with cipa/mig throughout showed a decline in serum CK l

  31. Slide 31: WORLDSymposium Update – Urine Hex4 Levels

    31 ERT-experienced patients treated with cipa/mig throughout experienced a decline in urine Hex4 levels in PROPEL that stabilized during the OLE. ERT-experienced patients who received alg/pla in PROPEL experienced an increase in Hex4 and a marked decline after switching to cipa/mig in the OLE ERT-na

  32. Slide 32: Thank you

    Thank you

Amicus Therapeutics — Investor Presentation (September 2023) on 6ix